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AB toxins are modular proteins that deliver their catalytic cargo into the 
cytosol of host cells. These toxins are increasingly being exploited for targeted 
delivery in biomedical and research applications due to their potency and cell 
specificity. This thesis explores the suitability of the cytotoxic necrotizing factor 
(CNF) family as a model system for the development of Bacterial Toxin-Inspired 
Drug Delivery (BTIDD) platforms. The CNF family is notable among AB toxins in 
that there are nine full-length homologs and many CNF-like catalytic domains 
associated with various other putative delivery systems. The data presented 
herein demonstrates how cargo and delivery modules of the CNF family 
members, CNF1, CNF2, CNF3, and CNFy, can be assembled to maintain 
efficient biological activity, and refines the joining sites for assembly of chimeric 
toxins to enhance their delivery efficiency. Through cell-based luciferase reporter 
assays, we show that the CNFy cargo domain is the most universally compatible 
and that the CNF3 delivery vehicle is the most flexible and efficient at delivering 
non-native cargo. Further, we show that the CNF3 delivery domain delivers the 
CNF2 and CNFy cargos more efficiently than their native delivery vehicles. We 
also investigated whether the previously reported differential sensitivity of the 
CNF toxins to endosomal acidification impacts their cargo delivery efficiency. We 
found that replacing particular acidic amino acid residues from the putative 
insertion-trigger motif of the CNFy translocation domain with those in CNF3 
promotes endosomal escape at a higher pH, leading to more efficient cytosolic 




bacterial toxins that can be exploited to optimize cytosolic delivery of biologic 
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Chapter 1: Cytotoxic Necrotizing Factors as a Model System to Study the 
Optimization of Bacterial Toxin-Inspired Drug Delivery Vehicles 
1.1 Targeted delivery of biologics 
Biologics or biological products are bioactive macromolecules, such as 
antibodies and small interfering RNAs, produced from living cells. The specificity 
and complexity of biologics allows for rational design of new therapeutics with a 
broad range of targets and function, but their clinical implementation has been 
largely limited to extracellular targets due to their inability to penetrate the cell. 
For example, antibody therapies have been employed to block the binding and 
subsequent cellular entry of bacterial exotoxins (93), but there are no therapeutic 
options on the market to combat toxins that have already entered affected cells. 
This is not due to a lack of therapeutics to counteract the intracellular activity of 
toxins, as monoclonal antibodies have been shown to reverse the proteolytic 
effects of botulinum neurotoxin (BoNT) serotypes A and B (32, 33). Yet, to date, 
there are no post-exposure toxin therapies to counteract intracellular acting 
toxins because a suitable delivery system for biologics is not currently available. 
Similarly, many oligonucleotide-based biologics are being developed for gene 
editing and gene silencing, yet delivering these therapies to the cytosol is still a 
significant barrier (37, 103, 104). As biologics grow in efficacy and availability, the 
question remains, how does one deliver biologics selectively into the cytosol?  
Several cytosolic delivery platforms have been explored. Platforms that 
encapsulate their protein or nucleic acid cargos, such as engineered 
nanoparticle-based carriers, polymer-drug conjugates and liposome formulations 




encapsulation strategies often suffer from the cargo becoming trapped within 
endosomes and diverted toward nonproductive intracellular trafficking pathways, 
leading to lysosomal degradation or recycling back to the surface (55). In 
contrast, bacterial virulence factors have naturally evolved to gain access into the 
mammalian cytosol to deliver potent effectors (11, 95). Of these virulence factors, 
a class of secreted proteins, known as AB toxins, inherently possess the ability to 
efficiently deliver various catalytic cargos into the host cell cytosol, so they are 
particularly attractive for the development of biologic delivery systems.  
 
1.2 Toxin-based cytosolic cargo delivery vehicles 
Many AB toxins are efficient molecular machines with exquisite potency 
and cell-targeting capabilities. The name “AB” represents their functional 
components or modules: an “A” module for the activity domain which houses the 
catalytic activity of the toxin and a “B” module for the binding domain which 
recognizes specific cell-surface receptors and elicits the uptake and subsequent 
delivery of the A module into the cytosol. Importantly, the modules of AB toxins 
can be separated from the holotoxin while still retaining their function. This 
enables the exploitation of the B modules of various toxins as vehicles to deliver 
non-native cargos into the cytosol of host cells in an approach we term Bacterial 
Toxin-Inspired Drug Delivery (BTIDD) (38). Indeed, many BTIDD systems are 
being developed using a variety of bacterial toxins, a select number of which I will 





Anthrax toxin is produced by Bacillus anthracis and is the causative agent 
of anthrax (21). This toxin is multi-partite, meaning multiple translated products 
come together to form the holotoxin. The B module consists of the protective 
antigen (PA), which binds to the cell and upon proteolytic activation can 
oligomerize to form a heptameric prepore. Multiple receptors have been 
described with binding affinity to PA, but tumor endothelial marker 8 (TEM8) and 
capillary morphogenesis gene 2 (CMG2) appear to be the main receptors (35). 
CMG2 is expressed on a variety of cell types, such that anthrax toxin could 
potentially affect many tissues. The catalytic A modules – lethal factor (LF) and 
edema factor (EF) – bind to the PA-prepore and the entire complex is 
endocytosed. Endosomal acidification triggers pore insertion and translocation of 
the A modules through the cation-selective PA-pore into the cytosol.  
The A-modules bind the heptameric pore in a 3:1 stoichiometry (35). LF is 
a 90-kDa zinc-dependent protease that inactivates members of the MAP kinase 
kinase family, leading to apoptosis of the intoxicated cell. EF is an 89-kDa 
adenylyl cyclase that raises cellular cAMP levels leading to swelling and affecting 
the transcriptional regulation of host factors. The N-terminal domain of lethal 
factor is responsible for binding to the PA-prepore to guide the cargo to the 
correct location for delivery into the cytosol. This N-terminal domain fragment, 
termed LFN, can be fused with other non-native cargos and facilitate their 
successful delivery into the cytosol of host cells (74). The PA/LFN system has 




domains of unknown function, such as that of the MARTX toxins (3). It has also 
been used to deliver heterologous cargo in the development of vaccines and 
cancer treatments (7, 88, 89). 
The advantage of this anthrax toxin-based system is that the well-
established mechanism of delivery allows for more informed modifications while 
designing recombinant delivery systems. A disadvantage is the multipartite 
nature of the toxin makes high-throughput production of prospective therapeutics 
more cumbersome as multiple subunits, namely PA and the LFN-cargo peptide 
fusion, must be purified and administered together in order to utilize this delivery 
system.  
Botulinum neurotoxins 
Botulinum neurotoxins (BoNTs) produced by the soil bacteria Clostridia 
botulinum are currently used in many biomedical applications for various 
neurological disorders and cosmetics (17, 57). These toxins exploit the 
internalization and acidification of synaptic vesicles to deliver their cargo 
intracellularly in neuronal cells at the neuro-muscular junction. This cell specificity 
allows for precise targeting and bolsters the potential to deliver therapeutic 
cargos to the neuronal system (101). 
The ~100-kDa heavy chain (HC) of the toxin is its B module with the cell-
binding domain at the C-terminal end (HC-C) and the translocation domain at the 
N-terminus (HC-N) (69). HC-C binds to two receptors, a polysialoganglioside 
(PSG) and a synaptic vesicle membrane protein on the presynaptic membrane 




delivers the A module, a ~50-kDa zinc-metalloprotease light chain (LC), into the 
cytosol. The HC and LC are co-expressed as a single polypeptide and post-
translationally processed to yield two peptide chains linked by a disulfide bond, 
which is reduced upon translocation of the LC into the cytosol. 
In the BoNT family, there are seven serotypes (A-G), each with their own 
subtypes, and the related tetanus neurotoxin (TeNT) produced by Clostridium 
tetani. BoNTs cause flaccid paralysis, while TeNT causes spastic paralysis (73, 
101). Being potent neurotoxins has earned the BoNTs a spot on the Center for 
Disease Control and Prevention’s list of Select Agents and Toxins, which makes 
research with these toxins non-trivial. Cumbersome though it may be, BoNT 
research has significantly advanced our understanding of AB toxin translocation 
and the study of this family as a whole has the potential to uncover the evolution 
of key molecular determinants in the intoxication process (56). Indeed, examining 
the amino acid sequences of the BoNT family has proved advantageous in 
identifying conserved residues important for cytosolic delivery (69).  
Diphtheria toxin 
Diphtheria toxin (DT) is a secreted virulence factor from Corynebacterium 
diphtheriae. This toxin is secreted as a single-chain peptide and undergoes 
proteolytic processing during the intoxication process to yield a 21.1-kDa N-
terminal A module and 41.2-kDa B module that remain connected by a disulfide 
bond (63). The B module binds the heparin-binding epidermal growth factor-like 
precursor (hb-EGF) and elicits uptake into an endocytic vesicle (64). Acidification 




membrane to create a cation-selective membrane pore required to deliver the A 
module into the cytosol (52). The catalytic A module inhibits translation by 
modification of elongation factor 2 (EF-2), ultimately leading to cell death and 
necrosis (20). This toxin has been employed in the clinic as an immunotoxin for 
selective killing of cancer cells by conjugating the translocation domain and 
catalytic ADP-ribosylating domain to specific receptor ligands that target and 
deliver the cell-killing cargo to the desired cell type (1). DT has been used to 
deliver vaccine epitopes (87), and various other non-native fluorescent and 
catalytic substrates inside of host cells (5). 
Advantages of DT-based delivery include the toxin’s small size, well-
characterized mechanism of early endosomal escape, and clinical efficacy. 
However, routine vaccination against DT means that most people are immunized 
against the toxin, so extra care must be taken to limit the immunogenicity of DT-
containing therapeutics (83). The disadvantage of using DT as a model system to 
study BTIDD is the lack of amino acid sequence homologs necessary for a 
comparative study, making it difficult to elucidate the types of modifications that 
can be made to modulate its native entry pathway.  
Adenylate cyclase toxin 
The adenylate cyclase toxin, CyaA, from Bordetella pertussis, the 
causative agent of whooping cough, is another toxin that shows promise for use 
as a vaccine-delivery vehicle (18, 90). CyaA is a major virulence factor 
responsible for immune modulation through its adenylate cyclase and hemolytic 




surface of CD11b-expressing phagocytic cells into the cytosol in an acidification-
independent manner (94). An inactive form of the toxin tolerates insertions of 
antigen epitopes within the catalytic CyaA domain, delivering them into the 
cytosol of immune cells to be processed and presented by MHC complexes (90). 
The resulting epitope delivery has been shown to elicit a strong CD8+ and CD4+ 
T-cell and antibody responses in mice. The precise targeting of CyaA to the 
immune system and its efficient cytosolic delivery directly from the plasma 
membrane make this toxin advantageous for immunotherapy. However, its 
precise translocation mechanism remains largely uncharacterized. The 
elucidation of this cytosolic delivery process would greatly aid the rational design 
of CyaA vectors, particularly in understanding how the insertion of specific 
epitopes may affect the structure and function of the toxin.  
Pasteurella multocida toxin 
Toxigenic strains of Pasteurella multocida produce a large, single-chain 
dermonecrotic toxin (PMT) (100). This protein toxin has its B module at the N-
terminus and its catalytic A domain at the C-terminus. The B module binds 
sphingomyelin and an unidentified protein co-receptor to enter host cells (14), 
and delivers its cargo into the cytosol through acidification-dependent 
translocation (75). The A module consists of an ~80-kDa heterotrimeric-G-
protein-activating domain that stimulates robust signaling changes, including 
activating mitogenic pathways, stimulating proliferation, actin-rearrangements, 
and differentiation (99). The N-terminal delivery vehicle has been shown to be 




cytosol of host cells (12, 19). PMT shares N-terminal homology with the family of 
cytotoxic necrotizing factors (CNFs) (100), which are the focus of this thesis.  
Limitations 
The BTIDD platforms described above have a clear preference toward the 
delivery of proteinaceous cargo, such as catalytic enzymes or antibodies, that 
can form stable fusion-proteins with the appropriate toxin component. I anticipate 
that the application of such platforms will be more practical and frequent as 
advancements are made in the development of biologics. During their 
formulation, it is imperative that these bioactive macromolecules are designed 
with their cytosolic-delivery mechanism in mind. Developers that choose to utilize 
the BTIDD approach will also need to assess the ability of their cargo to be 
delivered through the acidic endosomal environment.  
Further characterization of the native cytosolic delivery mechanisms of 
bacterial AB toxins will enhance the efficacy and rational design of BTIDD 
platforms. The examination of homologous toxin families is particularly 
informative in that their natural variation can be exploited to uncover molecular 
determinants that modulate intracellular delivery. This thesis further characterizes 
the single-chain cytotoxic necrotizing factor (CNF) family. The distinct nature of 
CNF homologs and their associated domains has the power to unveil key 






1.3 The cytotoxic necrotizing factor family  
CNF toxins are Rho-deamidating AB toxins that bind and enter host cells 
through receptor-mediated endocytosis, and subsequently translocate their cargo 
into the cytosol in a pH-dependent manner (50). These single-chain toxins have 
an N-terminal delivery vehicle and a C-terminal activity domain. Cytotoxic 
necrotizing factor 1 (CNF1), associated with Escherichia coli species isolated 
from human and animal infections, was the first of the CNF family described. 
Homologs of the CNF1 A domain are found associated with diverse intracellular 
delivery machinery, including Type III and Type VI Secretion Systems and other 
single-chain peptide delivery vehicles (102). This wide array of toxins containing 
CNF-like domains suggests that an evolutionary exchange or swapping of CNF 
modules occurred among bacterial species. Are these functional modules readily 
interchangeable or did they evolve to be compatible with their cognate cargo and 
delivery modules over time? How these cargo and delivery modules co-evolved 
for stable production and efficient cytosolic cargo delivery could uncover key 
compatibility features regarding the assembly of modular functional domains.  
There are nine full-length CNF homologs identified among pathogenic 
bacteria (Figure 1.1) (38). Each homolog has a high (54 - 85%) amino acid 
identity to CNF1 over the entire 1014 amino acid sequence (Figure 1.2). The fish 
pathogens Photobacterium damselae and Moritella viscosa encode CNFp and 
CNFm/CNFm2, respectively (45). CNFse was annotated from the zoonotic 
pathogen Salmonella enterica. CNFy is a secreted virulence factor in Yersinia 




CNF2, CNF3 and CNFx. CNF1 is associated with human urinary tract and 
meningeal infections, while CNF2 and CNF3 are associated with E.coli infections 
of cows, sheep and goats (50). Both CNF1 and CNF3 are located on the 
bacterial chromosome, while CNF2 is encoded on a transmissible plasmid.  
While CNF1, CNF2, CNF3 and CNFy all constitutively activate Rho-like 
GTPases, they differ in their substrate and receptor specificities, (13, 41, 91, 92), 
as well as in their sensitivity to endosomal acidification (76). CNF1 and CNF2 
both bind the laminin receptor, but CNF1 has a secondary receptor, the Lutheran 
blood group/basal cell adhesion molecule (Lu/BCAM) (60, 72). The receptors for 
CNF3 and CNFy have not been identified, but are both unable to enter Caco-2 
cells and reciprocally impair each other’s entry into HeLa cells, indicating they 
share a distinct receptor from that of CNF1 and CNF2 (91). CNF1, CNF2, CNF3 
and CNFy each constitutively activate small GTPases through deamidation, but 
they have been shown to differ in their substrate preference. CNFy preferentially 
activates RhoA (41), CNF2 activates both RhoA and Rac (92), while CNF1 and 
CNF3 activate RhoA, Rac and Cdc42 (40, 91). The acidification inhibitors NH4Cl 
and bafilomycin A1 block endosomal escape of CNF1, CNF2 and CNFy, but 
CNFy is much more sensitive than either CNF1 or CNF2 (76). The high identity 
among these toxins enables us to examine their limited sequence variation to 
identify discriminatory determinants responsible for the differences observed in 





1.4 Domain organization of the CNF toxins 
The studies described in this thesis utilize the toxin homologs CNF1, 
CNF2, CNF3 and CNFy. The CNF proteins are composed of an N-terminal 
receptor-binding domain (B), a C-terminal activity domain (A), and an 
interregional translocation domain (T) (Figure 1.3A). Previous studies utilizing N-
terminal truncations of CNF1 defined the A domain to consist of amino acids 720-
1014 (53). Histidine-881 and cysteine-866 form the catalytic dyad that is 
essential for G-protein deamidase activity (82) and are conserved in all of the 
CNF homologs (Figure 1.2). The crystal structure of the CNF1 A domain, 
residues 720-1014, shows the catalytic active site sandwiched between two beta 
sheets, each of which are flanked by alpha helices (15) (Figure 1.3B). Studies 
with CNF1 and CNFy chimeric peptides indicate that the flexible loop elements 
lining the catalytic pocket facilitate substrate recognition and specificity (40). 
An N-terminal region of CNF1 (amino acids 53-190) has been shown to 
interact with the laminin precursor receptor (LRP) and mature laminin receptor 
(LR) on human brain microvascular endothelial cells (29, 48, 60). CNF2 also 
binds to the LRP, but appears to have a weaker interaction with this receptor 
than CNF1 (60), indicating there may be another unidentified receptor for CNF2. 
A secondary receptor-binding site (B2) near the C-terminal cargo domain of 
CNF1 binds Lu/BCAM (residues 709-730) (72). CNF3 and CNFy share cell 
specificity with each other (91), but use an unidentified cellular receptor for entry 




A putative interregional translocation domain facilitates the endosomal 
escape of the C-terminal catalytic cargo of CNF1 (67). A 55-kDa fragment is 
cleaved from the rest of the toxin and released into the cytosol (49). Secondary 
structure predictions indicate that residues 349-412 form two hydrophobic alpha 
helices with an interior loop rich in acid amino acids. It has been suggested that 
this helix-loop-helix motif is responsible for the initial insertion event that 
potentiates translocation (10, 67), analogous to the double-dagger model 
proposed for DT (85) and BoNT (34, 61, 69). In this model, the negatively 
charged acidic residues within the loop are neutralized as the pH drops in the 
acidifying endosome. This shielding of negative charges allows association and 
subsequent insertion of the hydrophobic helices into the endosomal membrane. 
This potentiates pore formation and subsequent cargo delivery into the cytosol. 
In support of this model, mutations to change the acidic amino acids within the 
loop region of CNF1 to lysine residues (residues D373, D379, E382/E383), 
resulted in diminished cytotoxic effects (67).  
 
1.5 Aims: modulation of CNF toxin cytosolic cargo delivery  
BTIDD platforms exploit the native toxin cell-entry process to deliver 
therapeutics directly to the cytosol of host cells. This thesis explores the CNF 
family of bacterial toxins as a model system to study the modulation of cytosolic 
cargo delivery by AB toxins that enter the cell through the acidifying endosome.  
AB toxin modules are often exploited to achieve targeted delivery of 




function (105). Indeed, in the case of the CNF family, the existence of CNF-like 
domains associated with diverse functional components suggests that these 
modules are readily interchangeable (102). One of the key features of BTIDD 
platforms is their innate potency; however, the effect of domain-swapping on 
toxin efficiency is often overlooked. In chapter two, we investigate the 
compatibility of the CNF modules by swapping functional domains of homologous 
CNF toxins and comparing the effective concentrations of the resulting chimeras. 
The results provide a better understanding of inter-domain compatibility and 
refine the CNF domain boundaries. Further, we show that certain delivery 
vehicles are more flexible and efficient at cytosolic delivery (CNF3), even when 
delivering heterologous cargo (CNFy and CNF2). We anticipate that such studies 
will inform the functional assembly of modules within BTIDD platforms. 
The essential rate-limiting step of AB toxin bioactivity is characterized by 
the time required for endocytosis and trafficking to specific subcellular 
compartments (9, 28). This so called ‘lag phase’ after host-cell binding and 
before release into the cytosol, corresponds to when membrane translocation 
takes place. Therefore, efficient endosomal escape is a critical process that must 
be optimized in the design of single-chain BTIDD vehicles to avoid lysosomal 
degradation and promote cytosolic cargo delivery (55).  
CNF toxins translocate from the acidifying endosome in a pH-dependent 
manner (50). Previous studies indicate that CNF1, CNF2 and CNFy differ in their 
sensitivity to endosomal acidification inhibitors (76), but the molecular 




cell-based reporter assays of chimeric toxin peptides to uncover the pH-sensing 
determinants responsible for this differential sensitivity. Of the CNF toxins tested, 
we characterized CNF3 as the least sensitive to acidification inhibitors and 
confirmed CNFy as the most sensitive. Two residues within the translocation 
domain of CNFy and CNF3 were found to modulate the toxin response to 
endosomal pH. Further, we demonstrate that by replacing these two acidic 
residues of CNFy with the corresponding CNF3 residues we were able to 
enhance the delivery efficiency of CNFy. These results suggest that cytosolic 
delivery can be optimized through modifications to the translocation domain that 
potentiate endosomal escape at higher pH. We anticipate the results from these 
studies will inform the design of stable BTIDD platforms to improve their cargo 






Figure 1.1 Molecular phylogenetic analysis of the CNF toxin family by Maximum Likelihood 
method. Evolutionary analysis of the nine full-length CNF toxin homologs conducted in MEGA7 
(51). All positions containing gaps and missing data were eliminated, resulting in a total of 1004 
amino acid positions in the final dataset. The evolutionary history was inferred by using the 
Maximum Likelihood method (44), as previously described (38). The tree with the highest log 
likelihood is shown. The percentage of trees in which the associated taxa clustered together is 
shown next to the branches in blue. Initial tree(s) for the heuristic search were obtained 
automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances 
estimated using a JTT model, and then selecting the topology with superior log likelihood value. 
Branch lengths are listed below each branch and are measured in number of substitutions per 
site. The NCB Accession numbers for the sequences analyzed are listed below:  
 
CNFm NCB Accession # WP045110427,  
CNFm2 NCB Accession # WP075533205,  
CNFp NCB Accession # WP005306733,  
CNF1 NCB Accession # CAA50007,  
CNF2 NCB Accession # WP057108870,  
CNFse NCB Accession # WP079952502,  
CNF3 NCB Accession # WP024231387,  
CNFy NCB Accession # WP012304286  
















Figure 1.2 (cont.) 
 
Figure 1.2 Amino acid alignment of CNF toxin homologs shown in Figure 1.1. The high 
amino acid identity among the CNF toxin family is illustrated by the high degree of conservation 
through the entire length of the peptides, as published in (38). Alignment generated using Muscle 
(27) and visualized using Jalview (96) to color the amino acid residue sequences in Clustal 








Figure 1.3 The functional domains of CNF toxins as identified in CNF1. (A)The relative 
positions of each domain along the linear sequence of the amino acid peptide is illustrated: 
binding domain (B), translocation domain (T), domain of unknown function (DUF), secondary 
binding domain (B2), and activity domain (A). Putative insertion-trigger helix-loop-helix motif 
shown by multicolored alpha helices in the T domain. Estimated cleavage site shown with 
diagonal hash marks between the T domain and the DUF. The corresponding residue numbers 
are listed atop the domains. (B) Ribbon diagram of the CNF1 catalytic domain crystal structure 
(PDB 1HQ0; amino acid residues 720-1014) visualized using PyMOL (84). The catalytic active 
site residues Cys-866 (red) and His-881 (green) are shown in stick format. Loop 8, implicated in 





Chapter 2: Modular Domain Compatibility of CNF Toxins  
2.1 Introduction 
One of the greatest challenges to developing BTIDD systems is the 
assembly of heterologous modules into a recombinant protein that is stably 
expressed and highly efficient in delivering its cargo. Piggybacking heterologous 
cargo onto a full-length native toxin, rather than just the delivery module, has 
been used to circumvent this issue and enable more stable expression of the 
fusion protein (101). For example, fusions with full-length BoNT serotype D 
(BoNT/D) have been shown to deliver several enzymatically active cargos into 
the cytosol (8). Fusion proteins generated between PMT and the DT activity 
domain (DTa) showed 10-fold greater DTa-mediated activity when full-length 
PMT facilitated delivery, compared to a PMT-DTa fusion that did not include the 
PMT cargo (12). These data suggest that there are compatibility features 
between the cargo and delivery modules of AB toxins that facilitate the stability 
and function of the full-length toxin.  
The CNF toxin family is an attractive model system for the study of toxin 
evolution and domain compatibility. CNF effector-domain homologs indicate 
previous large-scale modular recombination events among bacteria (102), and 
could shed light on how these cargo modules evolved to be deliverable by 
various delivery modules. The nine high-identity, full-length CNF homologs have 
the potential to unveil small changes that maintained compatibility between the 




In the present study we utilize four CNF toxins: CNF1 CNF2, CNF3, and 
CNFy. The cargo and delivery modules were swapped among these CNF toxins 
to create chimeric proteins that were purified and assessed for their effective 
concentration in cell-based SRE-luciferase reporter assays (75, 76). Results 
revealed that the delivery module of CNF3 and the cargo of CNFy were more 
permissive than other CNF modules in that they did not negatively impact 
delivery efficiency when assembled with other non-native domains. In fact, the 
CNF3 delivery vehicle was found to enhance the cytosolic delivery efficiency of 
CNF2 and CNFy cargo. While chimeras with the CNFy delivery vehicle were 
more stably expressed, they were more restrictive in cargo compatibility. These 
findings indicate that while functional domains within proteins can be swapped, 
there are certain modules that more readily accommodate others for efficient 
function. Further, our results suggest that an individual domain could be 
engineered to be compatible with multiple partner domains. We anticipate that 
our insights could help inform chemical biology approaches to develop BTIDD 
platforms for cytosolic cargo delivery of therapeutics or molecular probes into 
mammalian cells. 
 
2.2 Design of chimeric CNF toxins  
The structural organization of the CNF proteins, as discussed in Chapter 
1, consists of an N-terminal receptor-binding domain (B), a C-terminal activity 
domain (A), and an interregional translocation domain (T) (Figure 2.1A). A 




in CNF1 (72). For the purpose of this study, the combined B and T domains are 
referred to as the ‘delivery vehicle’ that enables uptake and transport to the 
cytosol, while the A domain is referred to as the ‘cargo’ that harbors the toxic 
catalytic activity. 
 Immediately downstream of the N-terminal receptor-binding region is a 
stretch of amino acids (residues 219-225) that is identical in all four CNF1, CNF2, 
CNF3 and CNFy proteins. Site 223 within this conserved region was used as the 
joining site between the B domain and the T domain. As shown in Figure 2.1B, 
CNF1 and CNF2 are more closely related to each other than to CNF3 or CNFy 
within the B domain (amino acid residues 1-223), which is in line with the 
observation that both CNF1 and CNF2 share LRP-binding ability within the B 
domain (60). CNFy is more closely related to CNF3 than to CNF1 or CNF2, 
which is consistent with the observation that CNF3 and CNFy share cell 
specificity with each other, but apparently use an as-yet-unidentified cellular 
receptor for entry that is different from that of CNF1 and CNF2 (13, 91). 
Previous studies on CNF1 have defined the A domain to include amino 
acids 720-1014 (53), with the catalytic dyad histidine-881 and cysteine-866 
essential for deamidase activity (82). As such, position 720 was one of the sites 
used to join the delivery vehicle and cargo domains in our chimeric constructs. 
The sequences flanking residue 720 are not homologous among all the CNFs, 
but there is a stretch of 21 amino acid residues (674-694) upstream that is 100% 
conserved (Figure 2.1C). Hence, site 688 within this conserved region was also 




We also considered that the B2 domain identified in CNF1 spans across 
the 720 joining site. While an earlier study suggested residues 683-730 as an 
additional binding site for LRP (60), a later study showed that the region 709-730 
binds Lu/BCAM (72). The crystal structure of the CNF1 C-terminus (residues 
720-1014) indicates that residues 720-735 comprise an alpha helix situated on 
the external surface of the domain away from the active site (15). The N-terminal 
domain structure of amino acid residues 1-719 has yet to be solved. Thus, by 
modeling amino acid residues 706-719 onto the CNF1 crystal structure, we were 
able to extend the helix to include amino acid residues 706-735, as depicted in 
Figure 2.1D. This analysis was only done based on the structure of the CNF1 
activity domain, as currently there are no other crystal structures available for this 
toxin family. The B2 domain situated as an alpha helical region separate from the 
catalytic active site, suggests that the catalytic A domain may be further refined 
to amino acids 735-1014. To address the possibility that the delivery vehicle 
domain extends into the previously defined catalytic domain, we also used amino 
acid 735 as a joining site in our chimeric constructs. 
Based on the information above, we generated a series of chimeric toxin 
constructs and tested for their cellular activity using SRE-luciferase assays 
(Table 2.1). The chimeras are named by the wildtype CNFs used to create them 
in order from N to C terminus, followed by the amino acid position(s) of the 
joining site(s). For example, chimera CNF1y-735 consists of the CNF1 N-terminal 




735-1014. Only those protein constructs that were soluble were purified and 
utilized in our comparative analyses. 
 
2.3 Time course and dose response of wildtype CNF toxins  
To measure the successful cytosolic delivery of the CNF A domain, we 
took advantage of the fact that toxin-mediated activation of the small G-proteins 
RhoA, Rac, and Cdc42 results in downstream activation of SRE (39, 50). We 
compared the cellular activities of the toxins in HEK293-T cells by using the 
previously reported dual SRE-luciferase assay (2, 75, 76). 
Each wildtype CNF (CNF1, CNF2, CNF3 and CNFy) exhibited a distinct 
time and dose response profile (Figure 2.2). Similar to what was previously 
observed for CNF1 (76), the time course profiles were dependent on the toxin 
dose. Under our study conditions, we selected 0.85 nM as the toxin 
concentration for the time course, where CNF1 reached its maximum response in 
6-8 hours. In contrast, CNFy reached its maximum response in 10-12 hours, 
while CNF3 reached maximum activation in 8-10 hours. CNF2 reached its peak 
response in 8 hours and sustained it through 12 hours (Figure 2.2A). 
Based on the time course results, six hours was chosen as the toxin 
treatment time for subsequent dose response experiments to minimize the effect 
of differential downregulation of activated substrates. The dose-response curves 
for wildtype CNF1, CNF2, CNF3 and CNFy, shown in Figure 2.2B, were used to 




0.25 nM. A dose-response for CNF1 was included in all subsequent experiments 
for normalization. 
The differences observed among the toxin time course profiles and dose 
response curves reflect several factors including receptor specificity, the 
efficiency of receptor-mediated uptake, timing of endosomal escape, and 
substrate specificity. Experiments done with CNF1 and CNFy indicate that loop 8 
within the A domain is responsible for substrate recognition (40). CNF1 and 
CNF3 activate RhoA, Rac and Cdc42, but CNF3 has a 5-fold stronger activation 
of RhoA, compared to CNF1 (91). RhoA activation by CNF1 is downregulated by 
Cdc42-mediated degradation of RhoA (40), which may be responsible for the 
drop in reporter activity observed for CNF1 and CNF3 after 8 hours (Figure 
2.2A). In contrast, CNFy has a strong preference for RhoA activation (41). CNF2 
activates RhoA and Rac (92). Activated Rac is down-regulated by ubiquitin-
mediated degradation (25). This complex modulation of reporter activation 
through three possible substrates may also contribute to the observed 
differences in the toxins’ maximum dose responses (Figure 2.2B).  
Since substrate recognition is a function of the CNF cargo domain, to 
make accurate comparisons in terms of cell-entry and cargo-delivery capability, 
we must hold the catalytic cargo domain constant in subsequent analyses of the 





2.4 CNFy cargo, but not CNF3 cargo, is universally deliverable 
CNFy is the most distinct among the wildtype toxins in terms of amino acid 
identity, while CNF1 and CNF2 are the most closely related (Figure 2.1B). To test 
if the delivery vehicles of CNF1, CNF2, and CNF3 could deliver CNFy cargo, we 
created chimeric toxins CNF1y, CNF2y and CNF3y with three C-terminal joining 
sites 688, 720 and 735 (Figure 2.3A-C). The CNF1y construct joined at residue 
688 was not soluble, and thus, could not be tested in our cellular assays. CNF3y-
720 was not generated. 
Under our study conditions, wildtype CNFy had an EC50 of 0.25 nM. The 
chimeras CNF1y-720 and CNF1y-735 had EC50 values of 4.5 nM and 0.28 nM, 
respectively (Figure 2.3A). Chimeras CNF2y-688, CNF2y-720 and CNF2y-735 
had EC50 values of 2.5 nM, 2.4 nM and 0.99 nM, respectively (Figure 2.3B). 
Chimeras CNF3y-688 and CNF3y-735 had EC50 values of 0.076 nM and 0.82 
nM, respectively (Figure 2.3C). The chimeras joined at position 720 were less 
efficient at delivering CNFy cargo, which is consistent with the notion that joining 
at this site disrupts the secondary binding domain, B2.  
The dose response curves for all the chimeras with CNFy cargo, except 
CNF1y-720, appear the same or better than wildtype CNFy, indicating the 
delivery vehicles of CNF1, CNF2, and CNF3 are compatible with CNFy cargo. 
Chimera CNF3y-688 had the lowest EC50 value of 0.076 nM, indicating the most 
efficient delivery of CNFy cargo. While the calculated EC50 value of CNF3y-735 




an increase in maximum activation. It took less CNF3y-735 than CNFy to reach 
the same fold-activation at every point along the y-axis (Figure 2.3C). 
Since CNFy cargo is universal, in that it is delivered as or more efficiently 
than wildtype CNFy regardless of delivery vehicle (Figure 2.3A-C), we predicted 
that the CNF3 cargo would be similarly universal, as it is more closely related to 
CNF1 and CNF2 than CNFy (Figure 2.1B). Interestingly, chimeras CNF13-735, 
CNF23-735 and CNFy3-735 had EC50 values of 1.2 nM, 0.67 nM, and 0.59 nM, 
respectively (Figure 2.4A). These EC50 values are all at least 20-fold higher than 
that of wildtype CNF3, which has an EC50 value of 0.028 nM (Table 2.1). The C-
terminal joining site at amino acid 688 was also tested for each CNF3 cargo 
chimera and had similar or worse results (Figure 2.4B). These results indicate 
that CNF3 cargo is uniquely suited to its delivery vehicle, as chimeras with the 
delivery vehicle of CNF1, CNF2 and CNFy are significantly less efficient at 
CNF3-mediated reporter activation.  
  
2.5 CNFy delivery vehicle does not efficiently deliver heterologous cargo  
Next, we tested if the delivery vehicle of CNFy could deliver the cargo 
domains of CNF1, CNF2, or CNF3. Again, the resulting chimeras (CNFy1, 
CNFy2, and CNFy3) were joined at positions 688, 720 or 735, and their SRE-
reporter activations were compared with wildtype toxin having the same cargo 
domain. Chimeric toxins CNFy1-688, CNFy1-720, and CNFy1-735 had EC50 
values of 0.068 nM, 26 nM, and 6.7 nM, respectively (Figure 2.5A), all of which 




CNF2 had an EC50 value of 0.084 nM, whereas chimeric toxins CNFy2-688, 
CNFy2-720, and CNFy2-735 had higher EC50 values of 2.7 nM, 62 nM, and 2.8 
nM, respectively (Figure 2.5B). As observed for CNF1y, joining at position 735 
resulted in more efficient chimeras than joining at position 720 for both CNFy1 
and CNFy2 constructs. The CNFy delivery vehicle delivered CNF3 cargo less 
efficiently. CNFy3-688 and CNFy3-735 had EC50 values of 8.2 nM and 0.59 nM, 
respectively, as shown in Figure 2.4. 
Interestingly, CNFy1-688, which includes the putative CNF1 B2 domain, 
was the most efficient CNFy1 chimera (Figure 2.5A). In fact, the B2 domain of 
CNF1 appears to be essential for efficient delivery of CNF1 cargo as disruption 
(CNFy1-720) or exclusion (CNFy1-735) of the CNF1 B2 domain results in 
significantly decreased delivery efficiency (Table 2.1). However, this requirement 
for domain B2 to couple with its cognate cargo appears to be unique to CNF1, as 
interchanging the domain B2 of CNF2 or CNFy does not appear to alter the 
efficiency of CNF2 or CNFy cargo delivery, provided that the B2 region itself was 
not chimeric (Figures 2.5B and 2.3B). The CNFy delivery vehicle delivered CNF2 
cargo 32-fold less efficiently than wildtype CNF2, regardless of whether the 
putative B2 domain was from CNF2 or CNFy. 
Interestingly, if the entire B2 region was not that of CNF1, then CNFy1 
elicited higher maximum reporter activation (Figure 2.5A), suggesting differential 
stimulation of signaling pathways leading to reporter activity. The catalytic cargo 
domain defines the toxins’ specificity for the substrates that elicit the activation of 




cargo, the observed change in maximum reporter activation was not due to 
substrate specificity, but rather to altered substrate accessibility. Presumably, 
through interactions with the secondary Lu/BCAM receptor (72), the CNF1 B2 
domain could alter the intracellular trafficking and delivery of cargo to the cytosol, 
such that the catalytic domain has differential access to its substrates. More 
specifically, access to Cdc42 may be affected by CNF1 domain B2 receptor 
trafficking, as Cdc42 is not a substrate of CNF2 and delivery of CNF2 cargo is 
not affected by swapping the B2 region of CNF2 with CNFy (Figure 2.5B). These 
results highlight the importance of considering trafficking to different subcellular 
locations in the design of cargo-delivery vehicles, as it may alter access to 
substrates within the cytosol.  
 
2.6 CNF3 delivery vehicle enhances delivery efficiency of CNF2 and CNFy 
cargos 
Figure 2.3C showed that the CNF3 delivery vehicle was more efficient 
than wildtype CNFy at delivering CNFy cargo. To test if the delivery vehicle of 
CNF3 would also enhance the delivery of other homologous cargos, we 
generated chimeras CNF31 and CNF32 with joining sites at 688 and 735. 
CNF1 is the most efficient of the CNF toxins tested (EC50 = 0.018 nM). 
Unsurprisingly, the delivery vehicle of CNF3 was not able to enhance the efficient 
delivery of CNF1 cargo. CNF31-688 and CNF31-735 had EC50 values of 0.031 
nM and 0.071 nM, respectively (Figure 2.6A). Once again, the construct including 
the putative CNF1 B2 domain (CNF31-688) was the most efficient chimera. 




of CNF3 (EC50 values of 0.031 nM for CNF31-688, 0.028 nM for CNF3), 
suggesting the delivery vehicle limits the delivery efficiency. In other words, 
because CNF3 is less efficient than CNF1 in delivering their native cargo, the 
delivery vehicle of CNF3 cannot deliver any cargo more efficiently than native 
CNF3. Although CNF1 is the most efficient native toxin, it does not appear to be 
the most suitable for BTIDD applications. The CNF1 delivery vehicle failed to 
enhance delivery of CNFy and was 43 times less efficient at delivering CNF3 
cargo compared to their respective native vehicles 
CNF32-735 enhanced the delivery of CNF2 cargo beyond that of wildtype 
CNF2 delivery (EC50 = 0.084 nM). CNF32-688 and CNF32-735 had EC50 values 
of 0.19 nM and 0.029 nM, respectively (Figure 2.6B). Interestingly, the 735 
joining site was more efficient than the 688 joining site in this instance.  
Thus, the delivery efficiency appears to be limited by the toxins’ delivery 
module and the CNF3 delivery vehicle enhances the delivery efficiency of CNF2 
and CNFy cargos over that of their native vehicles (Figures 2.6 and 2.3C).  
 
2.7 Perspective 
The delivery modules of bacterial exotoxins, such as those found in the 
CNF family, are promising candidates for BTIDD platforms due to their targeted 
cell specificity and efficient translocation of cargo into the cytosol. The key to 
designing a universal cargo delivery platform will be successful fusion of the 




maintains potency. Here, we utilized the CNF family to assess the feasibility of 
such a platform.  
When recombining functional modules, it is important to consider the 
contribution of possible folding changes in the protein induced by generating 
impeding, or abolishing necessary, inter-domain interactions. While AB toxins 
have been shown to be modular in nature, when recombining their functional 
components, the inter-domain interactions may be altered between the modules. 
These factors can cause domain incompatibility by affecting the overall 
conformation of the protein and influencing the availability of receptor-binding 
domains, the response to pH that triggers and facilitates membrane translocation 
and the overall stability of the protein. We therefore chose to exchange domains 
of closely related CNF toxins to minimize the structural differences among the 
swapped modules and maintain overall structural integrity. 
Within the region surrounding the B2 joining sites (Figure 2.1C) there are 
multiple proline (Pro) residues. While most Pro residues are conserved among 
the CNF toxins in this region, there is some variation in the adjacent amino acid 
residues, such that the X-Pro imide bond might influence protein conformation. 
Likewise, the differences in side-chain charges of amino acids in this region 
could result in unfavorable interactions between the domains for pairing. 
However, we found no clear correlation among the CNF toxins and their chimeric 
pairings that would point to any specific contributing factor.  
During these studies, constructs containing the CNFy delivery vehicle 




CNF toxin preparations. Constructs containing a CNFy T domain were most 
abundantly expressed and most readily purified, indicative of a favorable and 
stable fold. However, the CNFy T domain does not appear to be flexible in 
accommodating concurrent changes in the flanking domains. Exchanging both 
the B and B2 domains of CNFy with that of CNF1 led to significantly decreased 
delivery efficiency of CNFy cargo, but individually exchanging the B or B2 domain 
had no effect on delivery efficiency (Figure 2.7). This suggests that the receptor-
binding domain(s) alone does not alter the cargo delivery efficiency by the 
translocation domain of CNFy. However, simultaneously altering the flanking 
regions may disrupt interactions necessary for cargo delivery even though the 
protein is stably and abundantly expressed. Similarly, all CNF1y1 chimeras 
generated were unable to deliver CNF1 cargo efficiently (Figure 2.8A). 
Consequently, we restricted further analyses to CNFy chimeras containing only a 
single joining site.  
In designing chimeric constructs, we considered the options of including 
the C-terminal B2 domain reported for CNF1 (60, 72), as part of the delivery 
vehicle (joining site 735), the cargo domain (joining site 688), or shared between 
the functional domains by joining at the previously defined catalytic domain 
boundary at position 720. Our results indicate that joining at position 720, which 
resides within the modeled α-helix of domain B2 (Figure 2.1D), is not tolerated as 
well as joining at either end of the B2 domain (position 735 or 688). This 
suggests that the B2 domain must remain intact and that the delivery vehicle 




boundaries within the toxin protein are important for identifying appropriate 
joining sites that allow the assembly of the different functional modules into 
stable and efficient cargo-delivery vehicles.  
As discussed for CNF1 in Section 2.5, different cellular receptor ligands 
could potentially affect substrate accessibility by altering the intracellular 
trafficking pathway. As AB toxins are taken up through the endocytic pathway, 
the endosomes formed at the periphery of the cell are subsequently trafficked 
toward the perinuclear region via microtubules (28, 42). As the endosome 
travels, it progressively acidifies and potentiates translocation of the cargo into 
the cytosol. Alterations in this trafficking pathway leading to different subcellular 
locations may alter access to substrates within the cytosol.  
Substrate access is also dependent on the timing of endosomal escape, 
which depends upon the pH that triggers translocation. CNF121 showed 
increased maximum reporter activation compared to CNF1 regardless of whether 
the B2 domain of CNF1 was disrupted (Figure 2.8B). The T domain of CNF2 has 
a higher pI (5.46) than that of CNF1 (4.89), and as such may require less 
acidification to neutralize acidic amino acid residues, enabling membrane 
association, insertion and subsequent escape from the endosome at earlier 
points along the trafficking pathway. This in turn may lead the catalytic A domain 
to have access to a differential composition of substrates at these varying points. 
For example, less stimulation of Cdc42, which normally downregulates RhoA 
(40), could lead to stronger responses through the RhoA and Rac pathways. In 




maximum activation due to crosstalk among the reporter signaling pathways, but 
this modulation would not be expected for cargos that act predominantly on a 
single substrate, such as CNFy.  
We show that CNFy requires a longer incubation time or higher dose than 
CNF1, CNF2 or CNF3 to reach its maximum reporter activation (Figure 2.2). 
CNFy has also been shown to need more time or a lower acidic pulse than CNF1 
to cross the biological membrane (13). Further, CNFy is more sensitive to 
acidification inhibitors than CNF1 and CNF2 (76). Thus, CNFy may remain longer 
in the acidifying endosome before reaching an optimal pH for translocation, 
thereby leading to more degradation of the toxin by trafficking through the 
lysosomal pathway. In line with this, trafficking of CNFy delivery vehicle through 
nonproductive pathways would explain the higher EC50 values observed for 
CNFy1, CNFy2, and CNFy3 compared to the delivery vehicles of CNF1, CNF2, 
or CNF3, respectively.  
The CNFy delivery vehicle appears better adapted to deliver the more 
closely related CNF3 cargo than CNF2 or CNF1 cargo, with fold increases in 
EC50 values of 21, 33 and >372, respectively (Table 2.1). In comparison, CNF1 
and CNF2 delivery vehicles deliver CNFy cargo, but not CNF3 cargo, as 
efficiently as their native delivery vehicles (Figure 2.9). This was unexpected, 
considering CNF3 is more closely related to CNF1 and CNF2 than CNFy is to 
CNF1 and CNF2 (Figure 2.1B). In fact, the CNF3 cargo appears uniquely 
adapted with its cognate delivery vehicle, as none of the vehicles tested could 




cargo appears universally deliverable, without deficit. CNFy cargo was delivered 
comparably by its cognate delivery vehicle and those of CNF1 and CNF2, and 
even better by the CNF3 delivery vehicle (Figure 2.9). Further comparative 
analysis of the universal CNFy cargo compared to the more restrictive cargos, 
such as CNF3, will be necessary to identify the features driving the compatibility 
of cargo and delivery vehicle.  
Further, the flexibility of CNFy cargo suggests that it may be engineered 
with a delivery vehicle to specifically enter target cells. For example, CNFy 
reportedly causes apoptosis specifically in prostate cancer cell lines due to its 
activation of cellular Rho GTPases (6), and so CNFy cargo could be coupled with 
a prostate cancer cell-targeting vehicle for anti-cancer therapeutic applications. 
CNF1 has also been explored for its therapeutic properties in treating neuronal 
disorders, such as Alzheimer’s disease and inflammatory pain (30). Including the 
B2 domain with the CNF1 cargo may assist in its efficient delivery to target cells. 
Although CNF3 was not more efficient than CNF1, it has the most flexible 
delivery vehicle, able to enhance delivery of those cargos whose vehicles are 
less efficient, such as CNF2 and CNFy. While CNF3 appears to be the most 
suitable as a universal cargo delivery vehicle among the CNF toxins, its 
application would require use of a different cell-specific receptor-binding domain 
since all the native CNF B domains are relatively nonspecific. Nevertheless, 
detailed examination of how CNF3 enhances the delivery efficiency of non-native 
(CNF2 and CNFy) cargo could provide insights regarding the design of optimal 




CNF delivery vehicles appear to be differentially optimized for delivering 
their cognate cargo domains. Indeed, the toxin with the most universal cargo 
(CNFy) has the least flexible delivery vehicle, and conversely, the toxin with the 
most universal delivery vehicle (CNF3) has the least flexible cargo. We suspect 
that those modules that are less flexible co-evolved to be more specific for their 
cognate partners restricting their compatibility with heterologous modules. This 
suggests that there are as-of-yet unidentified factors dictating compatibility 
among domains, and that contrary to the prevailing notion, arbitrary domain 
partnering can lead to detrimental outcomes, such as reduced expression, 
instability, and inefficient cargo-delivery function.  
Select members of the CNF family, namely the CNFy cargo and the CNF3 
delivery vehicle, display universality in that they may be partnered with domains 
from homologous toxins without impacting efficiency. Our results point to the 
practical feasibility of using chemical biology approaches to evolve flexible and 
tractable cargo-delivery platforms. Specifically, we envision our findings to be 
particularly beneficial for improving target-specific cytosolic cargo-delivery of 
therapeutics (BTIDD) or molecular probes in cell biology. 
 
2.8 Materials and methods 
Construction and purification of CNF toxin constructs  
Plasmids encoding the genes for CNF1 (pQE-CNF1), CNF2 (pProEx-
CNF2), and CNFy (pQE-CNFy) were obtained as previously described (76). The 




on GenBank #AM263062.1. The CNF genes were cloned into the pSuperG 
vector, a plasmid vector engineered in our laboratory to highly express 
recombinant His6-tagged proteins in E. coli. To facilitate domain swapping to 
generate chimeric toxins, restriction enzyme sites were introduced into the CNF 
gene sequences corresponding to amino acid positions 223 and 688 in the CNF1 
protein with conservative mutations. Joining at amino acid 720 was carried out by 
inserting a restriction site that resulted in the two amino acid insertion, E719-PG-
S720. The 735 joining site chimeras were generated using overlapping PCR 
primers. 
The His6-tagged CNF proteins were expressed in Top10 E. coli cells, with 
select constructs expressed under IPTG induction. The cells were harvested by 
centrifugation at 4,300 g. The pellets were resuspended in lysis buffer 
(phosphate buffered saline [PBS], pH 7.4, containing 0.5% IPEGAL nonionic 
detergent, 0.3 mg/mL lysozyme, 2 mg/mL benzamidine, 0.3 mg/mL 
phenylmethylsulfonyl fluoride, 5 Kunitz U/mL DNase, 10 µg/mL RNase, and 1 
µL/mL Sigma P8849 protease inhibitor cocktail), and lysed by sonication using a 
Braun-Sonic U ultrasonic cell disrupter on high setting, followed by centrifugation 
at 22,000 g and 4°C for 1.5 hours. The recombinant CNF proteins were purified 
by affinity chromatography using a Ni2+-NTA-agarose column (Qiagen, Valencia, 
CA, USA), followed by anion-exchange chromatography using a HiTrapQ column 
(Amersham-GE Healthcare Life Sciences, Pittsburgh, PA, USA). The resulting 
purified CNF proteins were desalted by gel filtration chromatography using a PD-




10% glycerol. All proteins were quantified by NIH Image J digital image analysis 
of Coomassie-stained SDSPAGE gels using BSA as the standard. Toxin 
samples were stored at -80°C until use.  
Cell culture 
HEK293-T cells (ATCC # CRL-11268) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Gibco-Invitrogen, Grand Island, NY, USA), 
supplemented with 0.37% sodium bicarbonate, 100 U/mL penicillin-streptomycin 
(ThermoFisher Scientific) and 10% fetal bovine serum (FBS, Atlanta Biologicals, 
Lawrenceville, GA, USA). The cells are maintained in DMEM with 5% or 10% 
FBS and stepped down to 2% FBS at the time of transfection before experiments 
were performed. 
SRE-luciferase assays 
HEK293-T cells in 24-well plates at 80% confluency were transfected 
using the calcium phosphate method, as previously described (18). Briefly, 
culture medium was changed immediately prior to transfection. Cells were 
transfected with two plasmids, one containing a SRE promoter fused to a firefly 
luciferase reporter gene (pSRE-luc, Stratagene) and the other containing a HSV-
TK promoter fused to the Renilla luciferase gene, acting as a low-expression 
constitutive reporter control gene (pGL4.74 hRluc/TK, Promega Madison, WI, 
USA) at a final DNA concentration in each well of 1.6 µg/mL pSRE-luc and 0.3 
µg/mL pGL4.74 hRluc/TK. While vortexing, a solution of the plasmids and 250 
mM CaCl2 was added dropwise to a solution of 2× HEPES-buffered saline, and 




added dropwise to each well. Cells were incubated for 7 hours, and then fresh 
DMEM containing toxin was added to the wells to give the indicated final 
concentration of toxin. After the cells were incubated for the indicated amount of 
time at 37°C, the medium was removed, and cells were lysed with 100 µL of 
Passive Lysis Buffer (Promega, Madison, WI, USA) per well. After 15 minutes 
incubation on a rocker, 10 µL of sample from the each well was transferred to a 
96-well plate, and the lysates were analyzed for firefly luciferase reporter activity 
and the constitutive Renilla luciferase control activity using the Promega Dual-
Luciferase® Reporter 1000 Assay System by addition of 25 µL of Luciferase 
Assay Reagent, followed by 25 µL of Stop and Glo Buffer per well, according to 
manufacturer's protocol. Luminescence was measured using a Synergy-HT 
multi-detection microplate reader (BioTek, Winooski, VT, USA), and results were 
generated using the Biotek microplate software Gen5 and reported as relative 
light units (RLUs), with settings: sensitivity = 108 and integration time = 1 s. 
Experiments were performed at least three independent times. For each 
experiment, all data points were performed in triplicate.  
Data analysis 
SRE-luciferase activity was determined by dividing the firefly RLUs by the 
Renilla control RLUs. The fold activation was determined by dividing the SRE-
luciferase activity for the toxin-treated samples by the mean SRE-luciferase 
activity for the untreated samples. To normalize between experiments, the fold 
activation was normalized to the maximum fold activation observed for CNF1. 




dose, plus or minus the standard deviation (SD). To calculate the dose response 
curves, the normalized fold activation for each well was compiled and analyzed 
with the Solver function in Microsoft Excel to create a best fit, four- parameter 
logistic (4PL) equation: y =F(x) = (A -D)/(1 + (x/C)^B ) +D, where A = minimum 
asymptote, B = slope, C = point of inflection or the EC50 value, and D = maximum 
asymptote. The best-fit curve was optimized for the least sum of the squared 
difference between observed and expected 4PL values. The standard deviation 
for the EC50 values was estimated from the y variance (σ2) of the curve-fitting 
and σ(x) ≈ ∆x⁄2, where ∆x is the difference in x for y =F(EC50) ± σ(y). 
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2.10 Table and figures 
Toxin EC50 (nM) EC50 
Ratio 
CNF1  0.018 ± 0.008  1  
CNFy1-688  0.068 ± 0.023  3.8  
CNFy1-720  >26 c  >1444c  
CNFy1-735  >6.7 c  >372 c  
CNF31-688  0.031 ± 0.009  1.7  
CNF31-735  0.071 ± 0.026  3.9  
CNF121-688  0.088 ± 0.049  4.9  
CNF121-720  0.079 ± 0.034  4.4  
CNF1y1-688  NDa  NDa  
CNF1y1-720  NDa  NDa  
CNF1y1-735  NDa  NDa  
CNF21-688  NDb  NDb  
CNF21-720  NDb  NDb  
 
Toxin EC50 (nM) EC50 
Ratio 
CNFy  0.25 ± 0.19  1  
CNF1y-720  4.5 ± 4.0  18  
CNF1y-735  0.28 ± 0.09  1.1  
CNF2y-688  2.5 ± 0.5  10.0  
CNF2y-720  2.4 ± 1.0  9.6  
CNF2y-735  0.99 ± 0.29  4.0  
CNF3y-688  0.076 ± 0.037  0.3  
CNF3y-735  0.82 ± 0.31  3.3  
CNF1y-223  1.8 ± 1.7  7.2  
CNF1y1y  NDa  NDa  
CNF1y-688  NDb  NDb  
 
 
Toxin EC50 (nM) EC50 
Ratio 
CNF2  0.084 ± 0.031  1  
CNFy2-688  2.7 ± 1.6  32  
CNFy2-720  62 ± 28  738  
CNFy2-735  2.8 ± 1.6  33  
CNF32-688  0.19 ± 0.08  2.3  
CNF32-735  0.029 ± 0.013  0.3  
CNF12-688  NDb  NDb  
CNF12-720  NDb  NDb  
 
Toxin EC50 (nM) EC50 
Ratio 
CNF3  0.028 ± 0.015  1  
CNF13-688  6.3 ± 1.4  225  
CNF13-735  1.2 ± 0.6  43  
CNF23-688  0.93 ± 0.85  33  
CNF23-735  0.67 ± 0.25  24  
CNFy3-688  8.2 ± 2.5  293  
CNFy3-735  0.59 ± 0.39  21  
 
 
Table 2.1 Effective concentrations of CNF toxins. EC50 Ratio was determined by dividing the 
EC50 of the chimera by that of the native CNF toxin with the same A domain.  
 
aNot determined- soluble protein was obtained, but maximum activation could not be determined. 
bNot determined- protein was insoluble and could not be purified. 





Figure 2.1 Construction of CNF chimeric toxins. (A) Schematic of CNF Toxin joining sites: The 
domain organization of the CNF protein sequence is depicted from N to C terminus with amino 
acid position of the putative domain boundaries indicated at the top. B, putative binding domain; 
T, putative translocation domain; B2, secondary binding domain (for CNF1); A, catalytic activity 
domain. (B) Percent Identity Tree for each domain. The alignment of protein sequences of CNF1, 
CNF2, and CNF3 from Escherichia coli, and CNFy from Yersinia pseudotuberculosis was 
generated using Muscle (27) and the neighbor-joining tree based on percentage identity was 
calculated using Jalview (96). Each tree is labeled in the upper left corner with domain and amino 
acid residues utilized to generate the alignment. The branch lengths are indicated for each 
(changes per 100 residues). The amino acid alignment of CNF1, CNF2, CNF3 and CNFy is 
available in Figure 2.10. (C) Location of the C-terminal joining sites on Wildtype CNF toxins. The 
alignment of protein sequences of CNF1, CNF2, CNF3, and CNFy was generated using Muscle 
and visualized using Jalview. The shading is based on conservation of amino acid residues. C-
terminal joining sites 688, 720, and 735 are denoted with arrows. The bar indicates the proposed 
secondary binding region modeled in Figure 2.1D, amino acid residues included within the crystal 
structure of CNF1 are highlighted in red and the modeled portion in yellow. (D) Structure of the C-
terminus of CNF1. Homology modeling using Modeller (97), based on the crystal structure of 
CNF1 (PDB 1HQ0; amino acid residues 720-1014) to include the proposed secondary receptor-
binding domain B2 (amino acid residues 706-735). Amino acid residues 720-735 (red) were 
defined in the crystal structure. The extended amino acid residues 706-719 (yellow) were 
rendered as part of an α-helix in the initial model and were refined after generating 3,000 models 
to find the lowest energy. The catalytic active site residues Cys-866 and His-881 are shown in 







Figure 2.2 Time course and dose response of wildtype CNF toxins. HEK293-T cells with 
reporter plasmids were treated with the indicated toxins and subjected to SRE-luciferase assay, 
as described in ‘Materials and methods.’ Each experiment was performed in triplicate. 
Normalization of fold activation is to the maximum activation of CNF1 as determined by the 4PL 
equation for each experiment. Data points shown are the mean values for that specified time or 
dose. Error bars represent the S.D. (A) Time course of cells treated with 0.85 nM toxin (CNF1 
green triangles, CNF2 blue circles, CNF3 purple diamonds, CNFy red squares) for the indicated 
times before analysis by SRE-luciferase assay. Data shown are the mean ± stdev of all points 
from 4 independent experiments for CNF1, CNF2 and CNFy (n=4), and from 2 independent 
experiments for CNF3 (n=2). Fold Activation values are in comparison to untreated cells. (B) 
Dose response curve for cells treated for 6 hours with the indicated toxins at the indicated doses 












Figure 2.3 (cont.) 
 
Figure 2.3 CNFy cargo is universally delivered by CNF1, CNF2, and CNF3 delivery 
domains. HEK293-T cells with reporter plasmids were treated with indicated toxin at the 
indicated doses and subjected to SRE-luciferase assay, as described in ‘Materials and methods.’ 
Fold Activation values are in comparison to untreated cells. Normalization of fold activation is to 
the maximum activation of CNF1 as determined by the 4PL equation for each experiment. 
Results shown are from 3 independent experiments where each data point was performed in 
triplicate (n=3). Data points shown are the mean values for that specified dose. Error bars 
represent the S.D. Composition of each chimeric toxin is shown above the corresponding plot. (A) 
Dose response curve comparing CNFy cargo delivered by CNF1 delivery vehicle (CNF1 green 
closed triangles, CNFy red closed squares, CNF1y-720 light green open triangles, CNF1y-735 
dark green open triangles). (B) Dose response curve comparing CNFy cargo delivered by CNF2 
delivery vehicle (CNF1 green closed triangles, CNFy red closed squares, CNF2y-688 yellow open 
circles, CNF2y-720 light blue open circles, CNF2y-735 dark blue open circles). (C) Dose 
response curve comparing CNFy cargo delivered by CNF3 delivery vehicle (CNF1 green closed 








Figure 2.4 CNF3 cargo is delivered less efficiently by CNF1, CNF2, and CNFy delivery 
vehicles. HEK293-T cells with reporter plasmids were treated with indicated toxin at the indicated 
doses and subjected to SRE-luciferase assay to determine the normalized fold activation relative 
to CNF1 and untreated cells, as described in Figure 2.3. Results shown are from 3 independent 
experiments where each data point was performed in triplicate (n=3). Data points shown are the 
mean values for that specified dose. Error bars represent the S.D. Composition of each chimeric 
toxin is shown above the corresponding plot. Dose response curves comparing CNF3 cargo 
delivered by CNF1, CNF2 and CNFy delivery vehicles at joining site 735 (A) or 688 (B). CNF1 
green closed triangles, CNF3 purple closed diamonds, CNF13-735 green open triangles, CNF23-
735 blue open circles, CNFy3-735 red open squares, CNF13-688 green open diamonds, CNF23-






Figure 2.5 CNFy delivery vehicle does not efficiently deliver heterologous cargos. HEK293-
T cells with reporter plasmids were treated with the indicated toxin at the indicated doses and 
subjected to SRE-luciferase assay to determine the normalized fold activation relative to CNF1 
and untreated cells, as described in Figure 2.3. Results shown are from 3 independent 
experiments where each data point was performed in triplicate (n=3). Data points shown are the 
mean values for that specified dose. Error bars represent the S.D. (A) Dose response curve 
comparing CNF1 cargo delivered by CNFy delivery vehicle (CNF1 green closed triangles, 
CNFy1-688 lime green open triangles, CNFy1-720 pale green open triangles, CNFy1-735 dark 
green open triangles). (B) Dose response curve comparing CNF2 cargo delivered by CNFy 
delivery vehicle (CNF1 green closed triangles, CNF2 blue closed circles, CNFy2-688 electric blue 






Figure 2.6 CNF3 delivery vehicle enhances delivery efficiency of CNF2, but not CNF1 and 
CNFy cargos. HEK293-T cells with reporter plasmids were treated with the indicated toxin at the 
indicated doses and subjected to SRE-luciferase assay to determine the normalized fold 
activation relative to CNF1 and untreated cells, as described in Figure 2.3. Results shown are 
from 3 independent experiments where each data point was performed in triplicate (n=3). Data 
points shown are the mean values for that specified dose. Error bars represent the S.D. (A) Dose 
response curve comparing CNF1 cargo delivered by CNF3 delivery vehicle (CNF1 green closed 
triangles, CNF31-688 lime green open diamonds, CNF31-735 dark green open diamonds). (B) 
Dose response curve comparing CNF2 cargo delivered by CNF3 delivery vehicle (CNF1 green 
closed triangles, CNF2 blue closed circles, CNF32-688 electric blue open diamonds, CNF32-735 
dark blue open diamonds). These experiments where performed simultaneously, so the CNF1 






Figure 2.7 Simultaneous exchange of the B and B2 domains of CNFy with that of CNF1 
leads to significantly decreased delivery efficiency by the CNFy T domain. Dose response 
curve comparing CNFy cargo delivered by CNFy translocation domain using the CNF1 receptor 
binding domains (CNF1 green closed triangles, CNFy red closed squares, CNF1y-223 dark blue 
open squares, CNF1y1y orange open squares). For comparison, the dose response curve for 
CNF1y1-688 (pale blue open squares) shown in Figure 2.8 is also included here. HEK293-T cells 
with reporter plasmids were treated with the indicated toxin at the indicated doses and subjected 
to SRE-luciferase assay to determine the normalized fold activation relative to CNF1 and 
untreated cells, as described in Figure 2.3. Results shown are from 3 independent experiments 
where each data point was performed in triplicate (n=3). Data points shown are the mean values 







Figure 2.8 The CNF2 T domain can be swapped into CNF1 without loss of efficiency, but 
the CNFy T domain is not. The receptor-binding domain and catalytic domain were previously 
identified in CNF1, so to generate chimeras swapping the T domain, we chose to hold the B and 
A domains of CNF1 constant, while exchanging domain T using the joining sites 223 and 688, 
720 or 735. HEK293-T cells with reporter plasmids were treated with the indicated toxin at the 
indicated doses and subjected to SRE-luciferase assay to determine the normalized fold 
activation relative to CNF1 and untreated cells, as described in Figure 2.3. Results shown are 
from 3 independent experiments where each data point was performed in triplicate (n=3). Data 
points shown are the mean values for that specified dose. Error bars represent the S.D. (A) Dose 
response curve comparing CNF1 cargo delivered by CNF2 translocation domain (CNF1 green 
closed triangles, CNF121-688 blue open circles, CNF121-720 pale green open circles). (B) Dose 
response curve comparing CNF1 cargo delivered by CNFy translocation domain (CNF1 green 
closed triangles, CNF1y1-688 blue open squares, CNF1y1-720 pale green open squares, 





Figure 2.9 Table of CNF results. Black numbers indicate the amino acid joining site residues for 
the chimeras; the joining site that is most efficient for that chimera is bolded. The shade of the cell 
indicates how the EC50 value of the best chimera of that type compares to the native CNF toxin 
with the same cargo, as designated by the ratios in Table 2.1. Cutoffs: Less efficient > 4 > 






Figure 2.10 Amino acid alignment of CNF toxins used in this study. The amino acid 
sequences of CNF1, CNF2, and CNF3 from Escherichia coli and CNFy from Yersinia 
pseudotuberculosis were aligned using Muscle (27) and visualized using Jalview (96) to color the 





Chapter 3: Differential Ammonium Chloride Sensitivity of CNF Toxins 
Unveils Acidification-Dependent Modulation of Cargo-Delivery Efficiency 
3.1 Introduction 
As AB toxins are taken up through the endocytic pathway, the endosomes 
formed at the periphery of the cell are subsequently trafficked toward the 
perinuclear region via microtubules (28, 42). As the endosomes travel, vesicles 
from the Golgi apparatus carrying vacuolar-type H+-ATPase (V-ATPase) fuse 
with the endosomes. These pumps transport protons into the lumen, 
progressively acidifying the endosome. Badizadegan, Collier, and Lencer outline 
the ‘lag phase’ of toxin entry to be defined by the time required for endocytosis 
and trafficking of AB toxins to their specific subcellular compartments where 
membrane translocation takes place (9, 28). They go on to characterize this lag 
phase as the essential rate-limiting step, after host-cell binding and before 
release into the cytosol. Efficient endosomal escape is a critical aspect of this 
lag-phase that must be optimized to avoid lysosomal degradation in the design of 
single-chain BTIDD vehicles (38), but their development is often hindered by the 
lack of a detailed understanding of the residues that respond to the endosomal 
environment to trigger the robust conformational change required to facilitate 
membrane interaction and channel formation for cargo translocation.  
For the CNF toxins and PMT, a hydrophobic helix-loop-helix insertion 
model has been proposed (10, 67) that is analogous to the double-dagger model 
proposed for DT (85) and BoNT (34, 61, 69). In this model, the double-dagger 
motif refers to a helix-loop-helix motif within the translocation domain. The 




dagger. As the pH drops in the acidifying endosome, these carboxylate residues 
are protonated which results in the loss of their negative charge, allowing the tip 
of the dagger to insert into the endosomal membrane. This initial membrane-
insertion event is thought to potentiate subsequent pore formation and cargo 
delivery into the cytosol.  
Unfortunately, there are not currently any crystal structures available for 
the N-terminal binding and translocation domain of the CNF toxin family. 
However, secondary structure predictions have been used to identify the 
corresponding putative helix-loop-helix motif in CNF1 (67). Our analyses show 
that this region is highly conserved among the CNF family (Figure 3.5A). 
Mutating the acidic amino acid residues within this putative loop (residues D373, 
D379, E382/E383) into lysine residues significantly reduced CNF1-mediated 
RhoA activation (67), supporting the importance of these residues in efficient 
CNF1 cellular intoxication.  
Here, we identified two additional amino acid residues, one at the loop tip 
and another at the base, within the CNF toxin insertion-trigger motif that 
modulate sensitivity to endosomal acidification and the toxin’s cargo-delivery 
efficiency. Results show that removing particular acidic amino acid residues from 
the insertion-trigger motif of the translocation domain promotes translocation at a 
higher pH, leading to more efficient cargo delivery. These findings provide an 
additional determinant of the insertion-trigger motif that can be exploited to 





3.2 CNF response to acidification inhibitors 
Acidification inhibitors, such as ammonium chloride (NH4Cl) and 
bafilomycin A1, raise intra-lysosomal and endosomal pH. NH4Cl chemically 
counteracts the acidification of the endosome (58, 65), while bafilomycin inhibits 
the V-ATPase proton pump (23). Both prevent the endosome from reaching the 
low pH necessary for cargo translocation by CNF1, CNF2 and CNFy in a dose 
dependent manner (76). To our knowledge, CNF3 had not been previously 
tested for its response to acidification inhibitors. Interestingly, in addition to 
exhibiting different cargo delivery efficiencies in HEK293T cells (38), all four 
CNFs have differential sensitivities to endosomal acidification inhibitors. These 
toxins were examined at both a uniform dose of 100 ng/mL (Figure 3.1A) and at 
their corresponding EC50 values (Figure 3.1B). In each case, CNFy was the most 
sensitive to NH4Cl treatment, requiring only 5 mM NH4Cl to block all CNFy-
mediated reporter activation, which agrees with previously published findings 
(76). CNF3 remained the least sensitive in each case. When tested at their 
respective EC50 values, CNF1 and CNF2 had very similar NH4Cl inhibition 
profiles, suggesting that they are triggered to escape the endosome at a similar 
pH value, but both toxins were less sensitive to NH4Cl than CNFy.  
In agreement with our findings, an earlier study reported that in the 
presence of bafilomycin A1, CNFy requires either a more acidic pulse (pH 4.8) or 
a longer exposure to the acidic pulse (30 min) to promote toxin translocation 
across the plasma membrane, compared to CNF1 (pH 5.2, 10 min) (13). These 




trigger endosomal escape, where toxins that are more sensitive to acidification 
inhibitors such as CNFy require a lower pH, while more tolerant toxins such as 
CNF3 can escape at a higher pH. We propose that optimizing the toxins to 
trigger translocation at a higher pH enables earlier endosomal escape and avoids 
lysosomal degradation of the cargo, thus enhancing their efficiency (Figure 3.2).  
 
3.3 Tracking the determinant responsible for sensing pH using chimeric toxins 
To identify the toxin determinants that modulate their pH sensitivity, we 
tested chimeric proteins with the N-terminal delivery domain of CNF3 and the 
cargo domain of CNFy (CNF3y) in cell-based reporter assays. Since CNF3 is the 
most tolerant to NH4Cl and CNFy is the most sensitive, we considered whether 
sensitivity of select CNF3y chimeras to NH4Cl would resemble that of CNFy or 
CNF3 (Figure 3.3). We applied an approach akin to a binary search by (1) 
selecting a joining site, (2) swapping the sequences, (3) assessing whether the 
resulting chimeras’ sensitivity to acidification resembled that of CNFy or CNF3, 
and then (4) selecting new joining sites either upstream or downstream of that 
site based on the result (Figure 3.3A). 
CNF3y-223 was joined downstream of the N-terminal receptor-binding 
domain (residues 53-190) (29, 60), such that it contained the receptor-binding 
domain of CNF3 and the putative translocation and cargo domains of CNFy. 
CNF3y-519 was joined upstream of the proposed cleavage site (residues 532-
544) (49), such that it contained the receptor-binding and putative translocation 




inhibited by 5 mM NH4Cl, similar to CNFy (Figure 3.3B), indicating that it is very 
sensitive to the inhibition of endosomal acidification. In contrast, CNF3y-519 was 
less sensitive to NH4Cl, resembling the inhibitor profile of CNF3. Since both 
chimeric toxins contained the same receptor-binding and cargo domains, these 
differences in sensitivity can be attributed to the putative translocation domain 
(residues 223-519).  
Additional joining sites at positions 317 and 428 were chosen based on 
the amino acid sequence alignment, secondary structure predictions, and 
regional isoelectric point (pI)calculations (Figure 3.4) to create CNF3y-317 and 
CNF3y-428, respectively. We selected joining sites at regions of high amino acid 
conservation and between predicted secondary structural elements in order to 
mitigate potential issues in protein folding and stability (Figure 3.4A). Figure 3.4B 
illustrates a representative example of the regional pI analysis of a predicted 
secondary structural element. Differences in isoelectric points were considered 
as the protonation state of charged residues impacts the regional charge, 
conformation and function of the protein. More specifically, the protonation of 
basic residues confers a positive charge that, in the case of toxin translocation, is 
proposed to promote ionic interactions with anionic lipids in the membrane, while 
protonation of acidic residues abolishes their negative charge to allow 
association and insertion into the membrane (69, 78). Their sensitivity profiles 
showed that CNF3y-317 is as sensitive to NH4Cl as CNFy, while CNF3y-428 is 
as tolerant as CNF3 (Figure 3.3C), narrowing the pH-sensing determinant to 




In this region, there is a pair of putative hydrophobic helices (residues 
349-412) thought to functionally resemble the double-dagger insertion helices 
TH8-9 of DT (DT residues 326-378) (67). To test the role of this insertion-trigger 
motif in sensing pH changes, three new chimeras were constructed: CNF3y-349, 
CNF3y-375 and CNF3y-412. The 349 joining site is directly in front of this motif, 
the 412 joining site is directly behind it, and the 375 joining site is within the 
putative acidic loop between the two helices. Their sensitivity profiles showed 
that CNF3y-349, like CNFy, is more sensitive to NH4Cl, while CNF3y-412 is more 
tolerant. CNF3y-375 has an intermediate profile, suggesting there are residues 
flanking this site that impact its response to acidification. CNF3y-412 also has a 
lower EC50 value of 0.07 nM, compared to CNF3y-349 and CNF3y-375, each 
with EC50 values of 0.2 nM. 
 
3.4 Point mutations confirm the modulating residues 
Further examination of the sequence alignment among the CNF homologs 
at the insertion-trigger motif revealed that CNFy has two additional acidic 
residues, E374 and E412, compared to the other CNF toxins (Figure 3.5A, red 
arrows). Acidic residues within the insertion-trigger motif are important regulators 
in the entry pathway of single-chain toxins. Previous studies showed that the 
acidic amino acids within the loop region of CNF1 (residues D373, D379, 
E382/E383) are important for toxin translocation (67), just as they are for DT 
(46). Unsurprisingly, those acidic residues studied in CNF1 are conserved in all 




observed differences in pH sensitivity. One of these additional acidic residues, 
E374, in CNFy was previously tested for its contribution to the lower pH needed 
to pulse CNFy across the plasma membrane (13). Although the investigators 
found that the E374Q mutation had no effect, they did not test the additional 
acidic residue at the base of the insertion-trigger motif, E412. Consequently, we 
made mutations at positions E374 and E412 in CNFy and the corresponding 
positions in CNF3 (Q373 and S411) to change one or both of these residues to 
the corresponding residue of the other toxin, and the resulting single and double 
mutant toxins were examined for their response to NH4Cl (Figures 3.5D-E). The 
CNF3 Q373E/S411E double mutant was less efficient than native CNF3 (EC50 
values of 0.1 nM and 0.04 nM, respectively) and more sensitive to NH4Cl 
(Figures 3.5 D&F). The CNFy E374Q/E412S double mutant was more efficient 
than native CNFy (EC50 values of 0.1 nM and 0.7 nM, respectively) and more 
tolerant of NH4Cl (Figure 3.5 E&G). The single mutants of both CNF3 and CNFy 
exhibited an intermediate response. These results are consistent with the 
previous study mentioned above, where mutating only one of the acidic residues 
in CNFy was not sufficient to significantly alter its response to pH (13), but by 
mutating both glutamate residues within this region to the corresponding residues 
of CNF3, we were able to enhance its tolerance to acidification inhibitors, 






The 7-fold enhanced efficiency of CNFy E374Q/E412S over native CNFy 
suggests that removing certain acidic amino acid residues from the insertion-
trigger motif promotes more efficient cargo delivery. Presumably this effect is due 
to lowering the number of negative charges that need to be protonated before 
membrane association and insertion can occur, which allows the toxin to escape 
at a higher pH and avoid lysosomal degradation. Specifically, we identify here 
two residues in the insertion-trigger motif of CNFy, which if mutated to replace 
these acidic residues with uncharged ones, not only make these toxins more 
tolerable to NH4Cl, but also enhance their cargo-delivery efficiency.  
A similar role for pH-sensing by acidic residues has been reported for 
BoNT serotype B (BoNT/B), where mutating three carboxylate residues within the 
translocation domain (HC-N) into amides resulted in increased translocation of 
the LC at earlier timepoints and at a less acidic pH (70). These results were more 
notable when multiple residues were mutated compared to single mutants, which 
is consistent with our observations in CNFy. This may account for the 
discrepancy reported previously, whereby Pei et. al did not observe any change 
in the pH required to pulse CNFy across the plasma membrane when only a 
single mutation was made (CNFy E374Q) (67). 
Just as previous results have shown that having too few acidic residues 
can diminish toxin delivery (67), our results indicate that too many can also be 
detrimental. These acidic residues serve as molecular sensors that trigger 




sensed by the acidification of the endosome. Triggering translocation at a neutral 
pH may lead to non-specific delivery, while triggering at a low pH increases the 
likelihood of being degraded by lysosomal hydrolases (Figure 3.2). Structural 
characterization of the CNF toxins would significantly improve the interpretation 
of such results, to identify the position of these acidic residues and whether they 
are exposed and accessible for membrane interaction.  
As AB-type bacterial protein toxins are increasingly employed as 
therapeutics (57, 59), it is imperative that we continue to investigate the intricate 
regulation of their cytosolic cargo-delivery mechanisms to optimize therapeutic 
potential. We anticipate these results will inform the translocation mechanism of 
CNF toxins and have broader implications for the development of BTIDD 
platforms. 
 
3.6 Materials and methods  
Construction and purification of CNF toxin constructs  
Plasmids encoding the genes for CNF1 (pQE-CNF1), CNF2 (pProEx-
CNF2), and CNFy (pQE-CNFy) were obtained as previously described (76). The 
CNF1, CNF2, CNF3 and CNFy genes were cloned into the pSuperG vector as 
previously described (38). To generate chimeric toxins, restriction enzyme sites 
were introduced into the CNF gene sequences corresponding to amino acid 
position 223 in the CNF3 and CNFy protein with conservative mutations. Joining 
at amino acid 519 was carried out by inserting a restriction site that resulted in 




at positions 317, 349, 375, 412, and 428 were generated using overlapping PCR 
primers, as were the single and double amino acid mutations.  
The His6-tagged CNF proteins were expressed in Top10 E. coli cells and 
purified as previously described (38). Briefly, the cells were harvested by 
centrifugation, resuspended in lysis buffer and lysed by sonication, followed by 
high-speed centrifugation to isolate the soluble fraction, which was then purified 
by affinity chromatography using a Ni2+-NTA-agarose column (Qiagen, Valencia, 
CA, USA) and anion-exchange chromatography using a HiTrapQ column 
(Amersham-GE Healthcare Life Sciences, Pittsburgh, PA, USA). The resulting 
proteins were desalted by gel filtration chromatography using a PD-10 column 
(Amersham-GE Healthcare Life Science), eluting with PBS containing 10% 
glycerol. All proteins were quantified by NIH Image J digital image analysis of 
Coomassie-stained SDSPAGE gels using BSA as the standard. Toxin samples 
were stored at -80°C until use.  
Cell culture  
HEK293-T cells (ATCC # CRL-11268) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Gibco-Invitrogen, Grand Island, NY, USA), 
supplemented with 0.37% sodium bicarbonate, 100 U/mL penicillin-streptomycin 
(ThermoFisher Scientific) and fetal bovine serum (FBS, Atlanta Biologicals, 
Lawrenceville, GA, USA). The cells are maintained in DMEM with 5% FBS and 






SRE-luciferase assays  
HEK293-T cells in 24-well plates at 80% confluency were transfected 
using the calcium phosphate method, as previously described (76). Briefly, 
culture medium was changed to 2% FBS DMEM immediately prior to 
transfection. Cells were transfected with two plasmids, one containing a SRE 
promoter fused to a firefly luciferase reporter gene (pSRE-luc, Stratagene) and 
the other containing a HSV-TK promoter fused to the renilla luciferase gene, 
acting as a low-expression constitutive reporter control gene (pGL4.74 hRluc/TK, 
Promega Madison, WI, USA) at a final DNA concentration in each dish of 3.2 
µg/mL pSRE-luc and 0.1 µg/mL pGL4.74 hRluc/TK. While vortexing, a solution of 
the plasmids and 250 mM CaCl2 was added dropwise to a solution of 2× HEPES-
buffered saline, and the resulting solution was incubated at room temperature for 
20 min and then added dropwise to each dish. Cells were incubated for 7 hours, 
and then split 1:1 into a 24-well plate for experiments. For inhibitor experiments, 
the next day fresh DMEM containing NH4Cl was added to the wells to give the 
indicated final concentration and incubated for 30 minutes before DMEM 
containing the indicated amount of toxin was added. The cells were incubated 
with toxin for 6 hours at 37°C, and then the medium was removed, and cells were 
lysed with 100 µL of Passive Lysis Buffer (Promega, Madison, WI, USA) per well. 
After 15 minutes incubation on a rocker, 25 µL of sample from each well was 
transferred to a 96-well plate, and the lysates were analyzed for firefly luciferase 
reporter activity and the constitutive Renilla luciferase control activity using the 




Luciferase Assay Reagent, followed by 25 µL of Stop and Glo Buffer per well, 
according to manufacturer's protocol. Luminescence was measured using a 
Synergy-HT multi-detection microplate reader (BioTek, Winooski, VT, USA), and 
results were generated using the Biotek microplate software Gen5 and reported 
as relative light units (RLUs), with settings: sensitivity = 108 and integration 
time = 1 s. Experiments were performed at least three independent times. For 
each experiment, all data points were performed in triplicate.  
Data analysis 
SRE-luciferase activity was determined by dividing the firefly RLUs by the 
Renilla control RLUs. The fold activation was determined by dividing the SRE-
luciferase activity for the toxin-treated samples by the mean SRE-luciferase 
activity for the untreated samples.  
In toxin dose-response experiments, to normalize between experiments, 
the fold activation was normalized to the range observed for CNFy. The 
normalized fold activation for each well was compiled and analyzed with the 
Solver function in Microsoft Excel to create a best fit, four- parameter logistic 
(4PL) equation: y = F(x) = (A -D)/(1 + (x/C)^B ) +D where A = minimum 
asymptote, B = slope, C= point of inflection or the EC50 value, and D = maximum 
asymptote. The best-fit curve was optimized for the least sum of the squared 
difference between observed and expected 4PL values. The standard deviation 
for the EC50 values was estimated from the y variance (σ2) of the curve-fitting and 




For the inhibitor response curves, the fold activation of control (PBS) treated 
cells were subtracted from each data point, and then normalized to the no-inhibitor 
treatment for that toxin. Data points shown are the means, plus or minus the 
standard deviation (SD). 
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Figure 3.1 CNF3 is the least sensitive to NH4Cl, CNFy is the most sensitive. HEK293T cells 
were treated with inhibitor for 30 minutes prior to treatment with 100 ng/mL of CNF toxin (A) or at 
their corresponding EC50 values (B). After 6 hours of incubation with toxin, the cells were lysed 
and the lysates were assayed for chemiluminescence, as described in ‘Materials and methods.’ 
Relative activity indicates each toxin’s fold SRE-luciferase activation compared to that of the 
same toxin with no inhibitor treatment. Each data point is the average of at least 3 independent 







Figure 3.2 Schematic of CNF toxin cell-entry. Upon binding of cell surface receptor and uptake 
into endocytic vesicles, CNF toxins are delivered into the cytosol by translocation from acidifying 
endosomes. Toxins that are less sensitive to acidification inhibitors escape the endosome at a 
relatively higher pH, avoiding lysosomal degradation. Here we identify amino acid determinants 
that respond to the acidifying environment to promote endosomal escape. Furthermore, we show 
that those toxins that are less sensitive to acidification inhibitors are also more efficient, which has 







Figure 3.3 Amino acid residues 349-412 are the determinants of NH4Cl sensitivity. (A) 
Schematic depicting the joining site of the chimeric constructs tested in (B)-(D) The functional 
domains of the toxin are listed above the schematic, where DUF = domain of unknown function 
and B2 = secondary receptor-binding domain. (B-D) HEK293T cells were treated similarly as in 
Figure 3.1B. The EC50 value of each toxin is indicated in the legend. Relative activity indicates the 
fold SRE-luciferase activation for each toxin compared to that of the same toxin with no inhibitor 
treatment. Each data point is the average of at least 3 independent experiments (n=3). Error bars 


















Figure 3.4 Analysis of CNF toxin amino acid alignment. (A) The alignment of the nine full-
length CNF homologs was used to generate a secondary structure prediction using Jpred 4 (26). 
Shown here is a representative section of the results from amino acids 360-440. The predicted 
secondary structural elements are indicated below the alignment (magenta helices and yellow 
beta strands). Joining sites 317 and 428 are delineated by red lines spanning the alignment and 
structural indicators. The joining sites were chosen such that they did not interfere with predicted 
secondary structure. (B) Representative analysis of a potential joining site location. Regions of 
CNF3 and CNFy that surround predicted structural elements (magenta helix shown below 













Figure 3.5 (cont.) 
 
Figure 3.5 Two residues within the CNF putative insertion helices modulate NH4Cl 
sensitivity. (A) Clustal alignment of CNF homologs and PMT. Cartoon under the alignment 
shows the location of the putative helix-loop helix motif and residues of interest (red arrows). (B-
C) Secondary structure modeled using HHpred (106) to align the putative helix-loop-helix region 
to existing PDB structures: CNF3 (PDB 3TX3 and PDB1Z67); CNFy (PDB 3TX3 and PDB 6D9Z); 
PMT (PDB 6D9Z). Model was colored to match the cartoon in (A) using PyMOL (84). (D-E) 
HEK293T cells were treated similarly as in Figure 3.1B. Relative activity indicates the fold SRE-
luciferase activation each toxin compared to that of the same toxin with no inhibitor treatment. 
Each data point is the average of at least 3 independent experiments (n=3). Error bars are ± SD. 
The EC50 value of each toxin calculated from the dose response curves in (F) and (G) is indicated 
in the legend. (F-G) HEK293-T cells with reporter plasmids were treated with indicated toxin at 
the indicated doses and subjected to SRE-luciferase assay, as described in ‘Materials and 
methods.’ Fold Activation values are in comparison to untreated cells. Normalization of fold 
activation is to the maximum activation of CNF3 (F) or CNFy (G) as determined by the 4PL 
equation for each experiment. Results shown are the means from 3 independent experiments 





Chapter 4: Implications and Impact 
4.1 A model of CNF endosomal escape 
Timing of cytosolic delivery 
Bacterial AB toxins traverse biological membranes and deliver their toxic 
catalytic cargo into the cytosol of host cells through diverse routes (Figure 4.1) 
(31, 98). Some toxins, such as CyaA, translocate their cargo directly across the 
plasma membrane into the cytosol (66), while “long trip” toxins, such as Shiga 
toxin produced by Shigella dysenteriae, exploit retrograde trafficking through the 
endoplasmic reticulum (ER) (81). “Short trip” toxins, like the CNF toxins, 
translocate from the acidifying endosome in a pH-dependent manner (50, 61). 
Each of these entry pathways ultimately lead to the cytosol, but as the names 
imply, their timing of cytosolic delivery varies. For example, CyaA immediately 
translocates and catalyzes the generation of cAMP (79, 80). In a direct 
comparison with anthrax edema factor (EF), which also catalyzes the formation 
of cAMP, but translocates from late endosomes, CyaA was shown to cause an 
earlier rise in cAMP (24). Conversely, retrograde trafficking is a much longer 
pathway to the cytosol through the trans-Golgi network and ER, requiring 
numerous host-cell factors (98). While it is largely accepted that these varying 
routes to the cytosol impact the timing of cargo delivery, temporal comparisons 
among toxins that utilize the same delivery pathway are largely lacking.  
For those toxins that translocate through the acidifying endosome, their 
timing of cargo delivery is dependent upon the pH that triggers endosomal 




and association with Rab-family GTPases (28, 42). Early endosomes (pH ~6.5) 
are associated with Rab5, while late endosomes (pH ~5.5) are associated with 
Rab7. The coordinated recruitment of Rab7 and loss of Rab5 is potentiated 
through a process known as Rab conversion (68, 77). The endosome 
progressively acidifies as the V-ATPase pumps protons into the lumen (28, 42), 
thus it takes more time for the endosome to reach a lower pH. Indeed, early 
kinetic studies on the endocytic uptake of the Semliki Forest virus showed that as 
early as 5 minutes after uptake the virus was exposed to pH ~6.2, while it took an 
average of 45 minutes for the endosome to reach pH ~5.3 (47). Earlier exit from 
the endo-lysosomal trafficking pathway not only gives a temporal advantage, but, 
perhaps more importantly, avoids lysosomal degradation.  
The previously observed differential response of the CNF toxin family to 
acidification inhibitors (76), prompted us to investigate the molecular 
determinants responsible for their differential pH sensitivity. In Chapter 3, we 
utilized cell-based reporter assays of chimeric toxin peptides to identify the 
modulating residues. Two residues within the translocation domain of CNFy and 
CNF3 were found to modulate the toxin response to endosomal pH. Further, we 
demonstrated that by replacing these two acidic residues of CNFy with the 
corresponding CNF3 residues we were able to make CNFy less sensitive to 
acidification inhibitors and enhance its overall efficiency.  
Our results suggest that CNF3 exits the acidifying endosome at higher pH, 
and thus, earlier than CNFy (Figure 3.2). In agreement with these findings, the 




reached its maximum reporter activation 4 hours after CNF3 and has a higher 
EC50 value, thus CNFy is less efficient than CNF3 (Figure 2.2). Combined, our 
studies also correlate toxin efficiency with their pH sensitivity, as the toxin least 
sensitive to acidification inhibitors (CNF3) was the most efficient cargo delivery 
vehicle, while the most sensitive toxin (CNFy) was the least efficient cargo 
delivery vehicle (Figure 2.9 and Figure 3.2). We show that by mutating the 
translocation domain of CNFy such that it is less sensitive to acidification 
inhibitors, its efficiency is enhanced (Figure 3.5). Thus, endosomal escape at a 
higher pH is beneficial to CNF cargo delivery efficiency.  
Subcellular location of endosomal escape  
The temporal differences discussed in the section above are also linked to 
spatial differences based on subcellular trafficking concurrent with endosome 
maturation. CNF toxins are taken up through receptor-mediated endocytosis by a 
clathrin-independent and caveolae-like-independent pathway and subsequently 
trafficked to late endosomes via microtubules (22, 50). The microtubular 
polymerization inhibitor nocodazole has been shown to halt the cellular activity of 
CNF1, CNF2 and CNFy (13, 76), indicating the progression from early to late 
endosomes is required for their escape. Late endosomes are routinely localized 
to the perinuclear region of the cell, while early endosomes are closer to the 
periphery (28, 42). As these compartments traffic to their respective subcellular 
destinations, escape at various points along the route may affect the regional 
concentration of the cytosolic cargo that is delivered (Figure 4.2). Similarly, 




of cargo delivery. These postulated cytosolic microdomains of cargo could affect 
the relative access to substrates within the cytosol and would explain the varying 
maximum in reporter activation we observed for certain constructs in Chapter 2. 
More work is needed to elucidate the subcellular trafficking by CNF toxins and 
the associated determinants responsible for delineating their route to the cytosol.  
  
4.2 The implications for development of intracellular delivery vehicles 
Compatibility 
BTIDD platforms exploit the native toxin cell-entry process to deliver 
therapeutics to the cytosol of host cells. Single-chain toxins contain all the 
functional elements for receptor recognition, membrane translocation and 
catalysis in one peptide strand. These sequential steps are carried out by distinct 
modules that can be interchanged while maintaining their respective functions. 
Well defined domain boundaries proved to be an important requirement 
for functional assembly. Contrary to previous studies that define residue 720 as 
the beginning of the catalytic activity domain (40, 53), we were able to more 
precisely refine the A domain to residues 735-1014. This distinction was made 
through careful consideration of the functional role reported for the adjacent 
receptor-binding domain (B2), as well as analysis of the amino acid sequence 
alignment and structural modeling (Figure 2.1). The importance of refining this 
domain boundary was evident, in that interrupting the B2 domain by joining 




In Chapter 2, we asked whether there are compatibility features between 
the CNF modules that evolved to accommodate their efficient cargo delivery. By 
swapping their functional domains and assessing the impact on cytosolic delivery 
efficiency, we showed that, indeed, certain delivery and cargo modules are more 
flexible in accommodating assembly with heterologous domains. The innate 
potency of bacterial toxins is a key feature of their therapeutic utility, however, 
the effect of domain-swapping on efficiency is often overlooked. There are a 
great many studies that utilize chimeric AB toxin molecules to demonstrate their 
ability to delivery non-native cargos into the cytosol of host cells, but most only 
ask if a cargo is successfully delivered, not to what extent.  
The work presented in Chapter 2 demonstrates that further investigation 
regarding the evolution of bacterial toxins has the potential to uncover 
determinants that are maintained for compatible assembly and those that are 
amenable to modification (38). For example, we found that CNF3 cargo is 
uniquely adapted to be delivered by its cognate delivery vehicle (Figure 2.4). Our 
study defined the cargo and delivery modules based on their previously reported 
functional domains and the sequence alignment of full-length CNF homologs, as 
reviewed in Sections 1.4 and 2.2. Thus, the catalytic A domain was referred to as 
the ‘cargo.’ However, more than just the catalytic domain is delivered into the 
cytosol (49). Figure 1.3 shows the C-terminal domains (DUF, B2 and A) that are 
released into the cytosol based on the location of the putative cleavage site. The 
function of these co-delivered domains is not clear. It could be that these 




Consistent with this idea, our lab recently found that the non-catalytic C-terminal 
cargo domains (C1-C2) of PMT are required to deliver the catalytic cargo domain 
(C3) into the cytosol (19). On-going work in our lab aims to elucidate whether the 
uncharacterized C-terminal CNF domains may function like C1-C2 of PMT to 
facilitate cytosolic cargo delivery. Further comparative studies of large toxin 
families, like those described above, will undoubtedly inform the compatible 
assembly of functional modules to develop universal cargo delivery systems.  
Endosomal escape 
Efficient endosomal escape is a critical process that limits the 
development of many intracellular delivery vehicles (55). As such, optimization of 
the determinants that trigger endosomal escape is a crucial consideration to 
avoid lysosomal degradation and promote cytosolic delivery. Our results suggest 
that the design of single-chain BTIDD vehicles can be optimized through 
modifications to the translocation domain that potentiate endosomal escape at a 
higher pH, perhaps by removing non-conserved acidic residues to lower the 
threshold of charges that require shielding to allow membrane association and 
insertion.  
Although there are many routes that can lead to the cytosol, alterations in 
the precise location of cytosolic delivery can lead to distinct subcellular 
localization of the cargo. This was beautifully illustrated using a cAMP fluorescent 
biosensor to visualize cAMP microdomains in intoxicated cells (24). CyaA 
translocation directly across the plasma membrane resulted in increased cAMP 




anthrax EF resulted in higher cAMP in perinuclear regions. Thus, it may be 
possible to exploit different pH-sensitive triggers to visualize the timing of 
endosomal escape and to deliver cargos to distinct locations within the cytosol 
corresponding to their cellular targets.  
 
4.3 Final remarks and remaining questions 
While there are a great many studies that exploit the ability to mix and 
match AB toxin modules, little work has been done to examine the interdomain 
interactions of the resulting fusion proteins. Here, we demonstrate the utility of 
the CNF toxin family as a model system to explore the functional impact of 
recombining delivery and cargo modules for cytosolic delivery of heterologous 
cargos. The precise molecular determinants for interdomain compatibility remain 
elusive. Crystal structures of the CNF N-terminal domains would greatly aid in 
the prediction of interdomain interactions and analysis of the results reported in 
this thesis. Specifically, the translocation domain structure would help elucidate 
the dynamic pH-sensitive rearrangements that facilitate translocation.  
We identify here two acidic amino acid residues within the CNFy 
translocation domain that were detrimental to the cargo delivery efficiency. It 
remains to be investigated whether an accumulation of negatively charged 
residues at the insertion-trigger motif can be detrimental to other toxins that enter 
through this pathway. It is a surprising result, considering acidic residues are 




The endocytic pathway is dynamic and elusive, with endosomes 
undergoing continuous maturation, fusion, fission and trafficking (43). Further 
characterization of the CNF toxins localization during intracellular trafficking is 
needed to elucidate how subcellular location affects cargo delivery. Interestingly, 
DT has been shown to decrease Rab conversion and increase the size of Rab5-
associated early endosomes from which it exits (4). This activity was attributed to 
insertion of the DT translocation domain, as two catalytically inactive T domain 
mutants known to inhibit translocation did not produce the same effects. Could 
early T domain insertion play a role in altering subcellular trafficking of the CNF 
toxins? Additional studies are needed to understand the molecular mechanisms 
behind trafficking of AB toxins through endosomal compartments.  
While early endosomal escape aids in avoiding lysosomal degradation, it 
is intriguing to consider the possible advantages of delayed escape. As 
discussed previously, it could be that trafficking toward the perinuclear region 
allows access to targets preferentially associated with late endosomes and 
lysosomal compartments. It could also serve as a method for colocalization with 
necessary host co-factors. Indeed, in vitro deamidation for CNFy is difficult to 
reproduce, indicating that CNFy may require unique cellular cofactors compared 
to the other CNF toxins (41). As the mechanism of CNF cleavage is still 
undetermined (49), it is possible that this low pH activates cellular proteases that 
release the CNF cargo from the rest of the peptide. 
While much remains to be learned, the CNF toxin family serves as a 




architecture, endocytic trafficking, and modulation of pH-dependent endosomal 
escape. The work described here highlights important design considerations for 
BTIDD systems, namely domain compatibility and the modulation of 
determinants that trigger endosomal escape. We anticipate these studies will 
inform the design of stable BTIDD platforms and the amino acid determinants of 








Figure 4.1 AB toxin routes to the cytosol. A schematic of subcellular trafficking routes leading 
to cytosolic delivery. Toxins can directly translocate across the plasma membrane (CyaA), 
escape from early or late endosomes in a pH-dependent manner (DT and CNF toxins), or exploit 
retrograde trafficking through the endoplasmic reticulum (Shiga toxin). Each of these entry 
pathways ultimately lead to the cytosol, but differ in their timing and location of cargo delivery. 







Figure 4.2 Model of spatio-temporal effects of endo-lysosomal trafficking on CNF cytosolic 
cargo delivery. As CNF toxins are taken up via receptor-mediated endocytosis, they are 
trafficked to early endosomes (pH ~6.5), which are associated with Rab5. Subsequent trafficking 
to Rab7-associated late endosomes (pH ~5.5) is facilitated by a dynamic network of microtubules 
and their associated motor proteins. As it is trafficked, the endosome progressively acidifies, 
potentiating translocation of toxin cargo into the cytosol. The pH that triggers endosomal escape 
may alter both the timing of delivery and subcellular location of the cargo; consider, for example, 
the difference between endosomal escape from endosomes A, B and C. Cellular receptors may 
also play a role in altering the subcellular trafficking and subsequent localization of the cargo; 
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